Navigation Links
ABCT, Connecticut’s Newest Accelerator Program for Biosciences Ventures, Announces 2019 Cohort of Life Science Startups

ABCT, the Accelerator for Biosciences in Connecticut, announced today the second cohort of emerging biosciences ventures invited to participate in the annual program. Twelve ventures will participate in the 6.5-month-long program that features business education to develop fundable business plans and a professional network. All startups receive an entrepreneur coach, access to active business professionals and preparation to pitch to investors.

The selected startups were chosen following an extensive screening process. Expert scientists, active investors and business strategists rated the ventures based on metrics such as the strength of the team, uniqueness of insights into the problems they are solving and their capacity to revolutionize the life sciences industry.

The 2019 ABCT 2019 cohort participants and ventures include:

  • Abbas Shojaee (Yale University) – MEaDvise is an intelligent chat bot able to conduct specialty medical interviews to help patients and physicians.
  • Caroline Dealy (UConn) – DeMay Bio is developing the first adjunct therapy for rheumatoid arthritis that targets the disease changes in the joints responsible for patient pain and disability.
  • Choukri Ben Mamoun (Yale University) – ELIV5 Therapeutics is developing a new class of antifungal drugs that target a critical step in vitamin B5 utilization required for pathogen survival and virulence.
  • Sorin Fideles (Yale University) – Based on novel insights into the biology of a new class of microRNAs, TargetSite Therapeutics is harnessing the power of a differentiated oligonucleotide therapeutic platform to target pro-inflammatory cytokines involved in therapeutic areas of distinct need.
  • VP Eswarakumar (Yale University) – Krouzon Pharmaceuticals is developing a first-in-class treatment for ultra-rare orphan pediatric skeletal disorders caused by fibroblast growth factor receptor 2 malfunction.
  • Ludmila Kvochina (Vanessa Research) – The MIDA Project is developing a high-throughput screen test for detection of microvillous inclusion disease (MVID) among patients with diarrhea.
  • Qi Zhao (Independent) – Enrich Therapeutics is working on phenotypical selection of individual therapeutic cells using a unique high-content discovery platform.
  • Tom Wenchell (Independent) – RevMedica is developing a technology platform for powered surgical instrumentation to provide the first-ever powered reusable endoscopic stapler that doesn’t require cleaning or sterilization.
  • Jeremy Miygul (Weill Cornell) – Developing a biofeedback device, consisting of a garment with embedded sensors and a downloadable software program, to allow users to perform biofeedback anywhere.
  • Vera Nezgovorova (Einstein) – Neurobot is a platform solution for people with compulsive, impulsive and autism spectrum disorders that comprises a wearable and AI-driven chat bot.
  • Brian Adams (Independent) – The Brain Institute of America’s goal is to increase the five-year survival rate for brain cancer patients by implementing innovative noncoding-RNA biomarker discovery platforms.
  • Mahmoud Morshedy (University of Bridgeport) – EnVision is a software program that improves communication, diagnostics and surgical accuracy by manipulating real patient images in holographic 3D using mixed reality technology.

Members of last year’s cohort have since accomplished a number of important milestones. Shoreline Biome closed its seed round and secured its first customer sale, as did LifeStyle CX, a lead-generation system for elder care facilities, and SolAware, which developed and distributes sun exposure monitoring systems to towns along the shoreline. Tissue Regeneration Sciences (TRS) closed a seed round based on NYU tissue reengineering technology. B2D2, a concussion diagnostic, will enter clinical trials in Australia in 2019 after spinning out from Weill Cornell’s pediatric neurology department. Lambda Vision, a UConn spinout, recently launched one of its experiments into space. For more information on these ventures and their successes, read the Impact Report for ABCT 2018.

ABCT also announced the addition of two new members to its team. Karolyn Rancourt Chamberlin will serve as Head of Mentorship, and Heidi Anderson will assume the role of Head of Coaching.

Finally, ABCT announced that Marcum LLP and Wilson Sonsini Goodrich & Rosati PC join CTNext, Purdue Pharma, Kaneka, Boehringer Ingelheim, Pfizer, Shipman and Goodwin, Wiggin and Dana, and AON as new corporate supporters.

About ABCT
ABCT is a competitive-entry, six-month-long program that helps emerging bioscience ventures grow by providing entrepreneurship education and business networking to access global funders and prospective team members. ABCT aims to support the development of Connecticut as a hub of bioscience invention and commercialization by harnessing the creativity and ambition present in the state’s academic institutions, spinouts from established institutions and serial entrepreneurs. It connects this talent with scientific experts and business leaders in Connecticut, New York City and around the world. ABCT supports young entrepreneurs by providing them with the education and networks critical to start successful bioscience-based businesses. For more information, visit

About Design Technologies
Design Technologies helps build emergent intellectual property (IP)–focused ventures and founded ELabNYC, the successful biosciences pre-accelerator program in New York City for research institution spinouts. ELabNYC ventures have raised over $300M, including Yiviva, a Yale spinout from Yung-Chi Cheng’s lab.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology technology :

1. Connecticut Bioscience Innovation Fund Invests $10 Million in Program in Innovative Therapeutics for Connecticut’s Health (PITCH)
2. Cynvenio Launches Newest LiquidBiopsy HER2 Expression Test
3. Life Creeps into Art at the Esther Klein Gallery’s Newest Exhibit
4. Newest Port Company Revolutionizing Antibody Discovery Platforms
5. LabKey Announces Newest Member of Panorama Partners Program
6. Ally Law Admits Newest Member in Paris, France
7. Newest Company at Science Center’s Port Business Incubator Developing Treatment for Rare Diseases
8. Hair Fairies Opens Newest Salon in Atlanta
9. Hair Fairies Lice Salon Finds its Newest Home in Seattle
10. Newest Esther Klein Gallery Exhibit Examines Technology’s Impact on the Psyche
11. Newest Startups at Science Center’s Port Business Incubator Tackling Viral Infections and Improving Cancer Treatment
Post Your Comments:
(Date:9/11/2019)... ... September 09, 2019 , ... ... trial randomization and drug supply chain management, today announced its new technology partnership ... sciences industry. , “The integration between Veeva Vault EDC and our IRT will ...
(Date:9/9/2019)... ... 09, 2019 , ... Visikol CEO Dr. Michael Johnson recently gave a ... to characterize 3D cell culture models. The inherent problem of characterizing 3D cell culture ... to image through and therefore traditional wide-field or even confocal microscopy only tells you ...
(Date:9/4/2019)... (PRWEB) , ... September 03, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... Director, Science & Technology will present at the upcoming Nordic Life Science ...
(Date:8/29/2019)... Kan. (PRWEB) , ... August 28, 2019 , ... ... expertise and wide-ranging DuPont™ Danisco® ingredient solutions to attendees at the International Baking ... to solve today’s baking challenges from optimizing production efficiency to cost and waste ...
Breaking Biology Technology:
(Date:8/14/2019)... ... , ... Gateway Genomics , a leading developer of direct-to-consumer genetic tests ... annual Inc. 500|5000 list of fastest growing private companies, in the first year ... and generating revenue by March 31, 2015. Ranking in the list is determined by ...
(Date:8/14/2019)... Calif. (PRWEB) , ... August 13, 2019 , ... Dr. Julie Reck of Veterinary ... to her patients. Her first stem cell patient, her own geriatric Australian Shepherd, ... According to Dr. Reck, Simon wanted to play but his body was weak, and he ...
(Date:8/6/2019)... , ... August 06, 2019 , ... ... a computational modeling system that could have far-reaching implications for personalized medicine, especially ... squares regression (PLSR), is able to predict which stem cell donors and manipulation ...
Breaking Biology News(10 mins):